222 related articles for article (PubMed ID: 22847606)
41. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival.
Kim NK; Baik SH; Seong JS; Kim H; Roh JK; Lee KY; Sohn SK; Cho CH
Ann Surg; 2006 Dec; 244(6):1024-30. PubMed ID: 17122629
[TBL] [Abstract][Full Text] [Related]
42. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
[No Abstract] [Full Text] [Related]
43. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Garcia-Aguilar J; Chow OS; Smith DD; Marcet JE; Cataldo PA; Varma MG; Kumar AS; Oommen S; Coutsoftides T; Hunt SR; Stamos MJ; Ternent CA; Herzig DO; Fichera A; Polite BN; Dietz DW; Patil S; Avila K;
Lancet Oncol; 2015 Aug; 16(8):957-66. PubMed ID: 26187751
[TBL] [Abstract][Full Text] [Related]
44. High EREG Expression Is Predictive of Better Outcomes in Rectal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy.
Lin CY; Hsieh PL; Chou CL; Yang CC; Lee SW; Tian YF; Shiue YL; Li WS
Oncology; 2020; 98(8):549-557. PubMed ID: 32408308
[TBL] [Abstract][Full Text] [Related]
45. Pretreatment HIF-1α and GLUT-1 expressions do not correlate with outcome after preoperative chemoradiotherapy in rectal cancer.
Havelund BM; Sørensen FB; Lindebjerg J; Spindler KL; Jakobsen A
Anticancer Res; 2011 May; 31(5):1559-65. PubMed ID: 21617210
[TBL] [Abstract][Full Text] [Related]
46. Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis.
Markovina S; Youssef F; Roy A; Aggarwal S; Khwaja S; DeWees T; Tan B; Hunt S; Myerson RJ; Chang DT; Parikh PJ; Olsen JR
Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):417-426. PubMed ID: 28871992
[TBL] [Abstract][Full Text] [Related]
47. The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.
Martinez-Useros J; Moreno I; Fernandez-Aceñero MJ; Rodriguez-Remirez M; Borrero-Palacios A; Cebrian A; Gomez Del Pulgar T; Del Puerto-Nevado L; Li W; Puime-Otin A; Perez N; Soengas MS; Garcia-Foncillas J
BMC Cancer; 2018 Feb; 18(1):144. PubMed ID: 29409457
[TBL] [Abstract][Full Text] [Related]
48. Focal adhesion kinase: predictor of tumour response and risk factor for recurrence after neoadjuvant chemoradiation in rectal cancer.
Gómez Del Pulgar T; Cebrián A; Fernández-Aceñero MJ; Borrero-Palacios A; Del Puerto-Nevado L; Martínez-Useros J; Marín-Arango JP; Caramés C; Vega-Bravo R; Rodríguez-Remírez M; Cruz-Ramos M; Manzarbeitia F; García-Foncillas J
J Cell Mol Med; 2016 Sep; 20(9):1729-36. PubMed ID: 27171907
[TBL] [Abstract][Full Text] [Related]
49. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
[TBL] [Abstract][Full Text] [Related]
50. Clinical implications of initial FDG-PET/CT in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
Lee SJ; Kim JG; Lee SW; Chae YS; Kang BW; Lee YJ; Park JS; Choi GS
Cancer Chemother Pharmacol; 2013 May; 71(5):1201-7. PubMed ID: 23420438
[TBL] [Abstract][Full Text] [Related]
51. YKL-40/c-Met expression in rectal cancer biopsies predicts tumor regression following neoadjuvant chemoradiotherapy: a multi-institutional study.
Senetta R; Duregon E; Sonetto C; Spadi R; Mistrangelo M; Racca P; Chiusa L; Munoz FH; Ricardi U; Arezzo A; Cassenti A; Castellano I; Papotti M; Morino M; Risio M; Cassoni P
PLoS One; 2015; 10(4):e0123759. PubMed ID: 25875173
[TBL] [Abstract][Full Text] [Related]
52. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
[TBL] [Abstract][Full Text] [Related]
53. Long-term prognostic value of mesorectal grading after neoadjuvant chemoradiotherapy for rectal cancer.
Madbouly KM; Hussein AM; Abdelzaher E
Am J Surg; 2014 Sep; 208(3):332-41. PubMed ID: 24581995
[TBL] [Abstract][Full Text] [Related]
54. What is the significance of the circumferential margin in locally advanced rectal cancer after neoadjuvant chemoradiotherapy?
Trakarnsanga A; Gonen M; Shia J; Goodman KA; Nash GM; Temple LK; Guillem JG; Paty PB; Garcia-Aguilar J; Weiser MR
Ann Surg Oncol; 2013 Apr; 20(4):1179-84. PubMed ID: 23328971
[TBL] [Abstract][Full Text] [Related]
55. Pathologic response grade after long-course neoadjuvant chemoradiation does not influence morbidity in locally advanced mid-low rectal cancer resected by laparoscopy.
Landi F; Espín E; Rodrigues V; Vallribera F; Martinez A; Charpy C; Brunetti F; Azoulay D; de'Angelis N
Int J Colorectal Dis; 2017 Feb; 32(2):255-264. PubMed ID: 27757541
[TBL] [Abstract][Full Text] [Related]
56. Upregulation of stromal cell-derived factor 1α expression is associated with the resistance to neoadjuvant chemoradiotherapy of locally advanced rectal cancer: angiogenic markers of neoadjuvant chemoradiation.
Kim HJ; Bae SB; Jeong D; Kim ES; Kim CN; Park DG; Ahn TS; Cho SW; Shin EJ; Lee MS; Baek MJ
Oncol Rep; 2014 Dec; 32(6):2493-500. PubMed ID: 25241658
[TBL] [Abstract][Full Text] [Related]
57. Combination of growth pattern and tumor regression identifies a high-risk group in neoadjuvant treated rectal cancer patients.
Jessberger J; Erlenbach-Wünsch K; Posselt R; Haderlein M; Agaimy A; Fietkau R; Hartmann A; Distel L
J Dig Dis; 2017 May; 18(5):283-291. PubMed ID: 28342240
[TBL] [Abstract][Full Text] [Related]
58. Significant correlation between LKB1 and LGR5 gene expression and the association with poor recurrence-free survival in rectal cancer after preoperative chemoradiotherapy.
Saigusa S; Inoue Y; Tanaka K; Toiyama Y; Kawamura M; Okugawa Y; Okigami M; Hiro J; Uchida K; Mohri Y; Kusunoki M
J Cancer Res Clin Oncol; 2013 Jan; 139(1):131-8. PubMed ID: 22986809
[TBL] [Abstract][Full Text] [Related]
59. Adjuvant Chemotherapy Does Not Improve Recurrence-Free Survival in Patients With Stage 2 or Stage 3 Rectal Cancer After Neoadjuvant Chemoradiotherapy and Total Mesorectal Excision.
Voss RK; Lin JC; Roper MT; Al-Temimi MH; Ruan JH; Tseng WH; Tam M; Sherman MJ; Klaristenfeld DD; Tomassi MJ
Dis Colon Rectum; 2020 Apr; 63(4):427-440. PubMed ID: 31996583
[TBL] [Abstract][Full Text] [Related]
60. [Long-term prognostic analysis on complete/near-complete clinical remission for mid-low rectal cancer after neoadjuvant chemoradiotherapy].
Wang L; Li S; Zhang X; Sun T; Du C; Chen N; Peng Y; Yao Y; Zhan T; Zhao J; Cai Y; Li Y; Wang W; Li Z; Sun Y; Ji J; Wu A
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1240-1248. PubMed ID: 30506534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
